Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset "INTRECIS"


Phase N/A Results N/A

Summary of Purpose

Stroke is one of the leading causes of death and disability in China. Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) improves the outcome for ischemic stroke patients who can be treated within 4.5 hours of symptom onset. In China, in addition to rt-PA, intravenous urokinase within 6 h has also been recommended by the 2010 Chinese Guidelines for the Diagnosis and Treatment of...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 27 November 2017.

1 Dec 2016 29 Jul 2016 1 Feb 2019 1 Aug 2019 1 Nov 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample


See All